Pet/Mri enters the us market
Posted: Mon Dec 01, 2014 6:02 pm
Article dated
September 26, 2011
Cancer is the second-leading cause of death in the United States, with heart-related diseases being the first. Approximately 1.44 million new cases will be diagnosed in 2007, with 560,000 deaths.1 Overall cancer death rates have decreased since 1990, mainly due to early detection of certain cancers such as prostate and breast, but cancer incidence for some tumor types has increased.3 Given various changes in demographics, the incidence of cancer in the United States likely will double by 2050.4 These statistics point to the urgent need of improved treatment modalities.
Identification and selection of potentially active anticancer agents has largely been based on screening large numbers of compounds, aided by rational drug design when the molecular structure of the target is known. Once compounds have been selected on the basis of specificity for the target and desired functional effect, the ultimate test for advancement of a compound to clinical evaluation is to show its safety and efficacy in animal tumor models. Subcutaneous human tumor xenograft models are used widely because they recapitulate many aspects of the biology of human tumors, including sensitivity to anticancer agents.8 Tumors can be implanted subcutaneously in mice as fragments by the use of a trocar or as cell suspensions. The large subcutaneous space in rodents allows for continuous growth of the tumor.
The methods used by the industry to measure tumor characteristics vary in technical approach, versatility, performance and cost. General properties of these methods are summarized in Table 1.
http://www.dicardiology.com/article/pet ... s-market-0
September 26, 2011
Cancer is the second-leading cause of death in the United States, with heart-related diseases being the first. Approximately 1.44 million new cases will be diagnosed in 2007, with 560,000 deaths.1 Overall cancer death rates have decreased since 1990, mainly due to early detection of certain cancers such as prostate and breast, but cancer incidence for some tumor types has increased.3 Given various changes in demographics, the incidence of cancer in the United States likely will double by 2050.4 These statistics point to the urgent need of improved treatment modalities.
Identification and selection of potentially active anticancer agents has largely been based on screening large numbers of compounds, aided by rational drug design when the molecular structure of the target is known. Once compounds have been selected on the basis of specificity for the target and desired functional effect, the ultimate test for advancement of a compound to clinical evaluation is to show its safety and efficacy in animal tumor models. Subcutaneous human tumor xenograft models are used widely because they recapitulate many aspects of the biology of human tumors, including sensitivity to anticancer agents.8 Tumors can be implanted subcutaneously in mice as fragments by the use of a trocar or as cell suspensions. The large subcutaneous space in rodents allows for continuous growth of the tumor.
The methods used by the industry to measure tumor characteristics vary in technical approach, versatility, performance and cost. General properties of these methods are summarized in Table 1.
http://www.dicardiology.com/article/pet ... s-market-0